BOSTON SCIENTIFIC CORP (BSX.DE) Fundamental Analysis & Valuation

FRA:BSX • US1011371077

Current stock price

60 EUR
+0.6 (+1.01%)
Last:

This BSX.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. BSX.DE Profitability Analysis

1.1 Basic Checks

  • BSX had positive earnings in the past year.
  • BSX had a positive operating cash flow in the past year.
  • BSX had positive earnings in each of the past 5 years.
  • Each year in the past 5 years BSX had a positive operating cash flow.
BSX.DE Yearly Net Income VS EBIT VS OCF VS FCFBSX.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B 4B

1.2 Ratios

  • BSX has a Return On Assets of 6.64%. This is in the better half of the industry: BSX outperforms 75.81% of its industry peers.
  • Looking at the Return On Equity, with a value of 11.96%, BSX is in the better half of the industry, outperforming 75.81% of the companies in the same industry.
  • Looking at the Return On Invested Capital, with a value of 8.70%, BSX is in the better half of the industry, outperforming 69.35% of the companies in the same industry.
  • BSX had an Average Return On Invested Capital over the past 3 years of 7.70%. This is below the industry average of 10.01%.
  • The last Return On Invested Capital (8.70%) for BSX is above the 3 year average (7.70%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 6.64%
ROE 11.96%
ROIC 8.7%
ROA(3y)5.27%
ROA(5y)4.17%
ROE(3y)9.54%
ROE(5y)7.64%
ROIC(3y)7.7%
ROIC(5y)7.08%
BSX.DE Yearly ROA, ROE, ROICBSX.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30

1.3 Margins

  • Looking at the Profit Margin, with a value of 14.44%, BSX belongs to the top of the industry, outperforming 85.48% of the companies in the same industry.
  • BSX's Profit Margin has improved in the last couple of years.
  • Looking at the Operating Margin, with a value of 19.92%, BSX belongs to the top of the industry, outperforming 82.26% of the companies in the same industry.
  • In the last couple of years the Operating Margin of BSX has grown nicely.
  • With an excellent Gross Margin value of 69.01%, BSX belongs to the best of the industry, outperforming 80.65% of the companies in the same industry.
  • BSX's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 19.92%
PM (TTM) 14.44%
GM 69.01%
OM growth 3Y6.86%
OM growth 5Y16.97%
PM growth 3Y41.81%
PM growth 5YN/A
GM growth 3Y0.01%
GM growth 5Y1.13%
BSX.DE Yearly Profit, Operating, Gross MarginsBSX.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. BSX.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BSX is destroying value.
  • BSX has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for BSX has been increased compared to 5 years ago.
  • Compared to 1 year ago, BSX has an improved debt to assets ratio.
BSX.DE Yearly Shares OutstandingBSX.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B
BSX.DE Yearly Total Debt VS Total AssetsBSX.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B 40B

2.2 Solvency

  • An Altman-Z score of 4.22 indicates that BSX is not in any danger for bankruptcy at the moment.
  • With a decent Altman-Z score value of 4.22, BSX is doing good in the industry, outperforming 75.81% of the companies in the same industry.
  • The Debt to FCF ratio of BSX is 3.13, which is a good value as it means it would take BSX, 3.13 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 3.13, BSX is in the better half of the industry, outperforming 74.19% of the companies in the same industry.
  • BSX has a Debt/Equity ratio of 0.46. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.46, BSX is in line with its industry, outperforming 50.00% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF 3.13
Altman-Z 4.22
ROIC/WACC0.85
WACC10.25%
BSX.DE Yearly LT Debt VS Equity VS FCFBSX.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B 15B 20B

2.3 Liquidity

  • BSX has a Current Ratio of 1.62. This is a normal value and indicates that BSX is financially healthy and should not expect problems in meeting its short term obligations.
  • BSX has a Current ratio (1.62) which is comparable to the rest of the industry.
  • A Quick Ratio of 1.08 indicates that BSX should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.08, BSX is in line with its industry, outperforming 50.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.62
Quick Ratio 1.08
BSX.DE Yearly Current Assets VS Current LiabilitesBSX.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. BSX.DE Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 21.51% over the past year.
  • Measured over the past years, BSX shows a very strong growth in Earnings Per Share. The EPS has been growing by 26.01% on average per year.
  • BSX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.88%.
  • BSX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.16% yearly.
EPS 1Y (TTM)21.51%
EPS 3Y20.34%
EPS 5Y26.01%
EPS Q2Q%14.29%
Revenue 1Y (TTM)19.88%
Revenue growth 3Y16.54%
Revenue growth 5Y15.16%
Sales Q2Q%15.9%

3.2 Future

  • The Earnings Per Share is expected to grow by 13.13% on average over the next years. This is quite good.
  • Based on estimates for the next years, BSX will show a quite strong growth in Revenue. The Revenue will grow by 10.46% on average per year.
EPS Next Y14.65%
EPS Next 2Y13.93%
EPS Next 3Y13.32%
EPS Next 5Y13.13%
Revenue Next Year10.92%
Revenue Next 2Y10.66%
Revenue Next 3Y10.49%
Revenue Next 5Y10.46%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
BSX.DE Yearly Revenue VS EstimatesBSX.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 10B 20B 30B 40B
BSX.DE Yearly EPS VS EstimatesBSX.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2 4 6

More info and screens

Find the best growth stocksShow best growing peers

4

4. BSX.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 22.81, BSX is valued on the expensive side.
  • Based on the Price/Earnings ratio, BSX is valued a bit cheaper than 64.52% of the companies in the same industry.
  • BSX's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 25.61.
  • With a Price/Forward Earnings ratio of 19.89, BSX is valued on the expensive side.
  • BSX's Price/Forward Earnings is on the same level as the industry average.
  • The average S&P500 Price/Forward Earnings ratio is at 22.79. BSX is around the same levels.
Industry RankSector Rank
PE 22.81
Fwd PE 19.89
BSX.DE Price Earnings VS Forward Price EarningsBSX.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • The rest of the industry has a similar Enterprise Value to EBITDA ratio as BSX.
  • BSX's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 28.21
EV/EBITDA 20.99
BSX.DE Per share dataBSX.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • The excellent profitability rating of BSX may justify a higher PE ratio.
  • BSX's earnings are expected to grow with 13.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.56
PEG (5Y)0.88
EPS Next 2Y13.93%
EPS Next 3Y13.32%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BSX.DE Dividend Analysis

5.1 Amount

  • No dividends for BSX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BSX.DE Fundamentals: All Metrics, Ratios and Statistics

BOSTON SCIENTIFIC CORP

FRA:BSX (3/25/2026, 7:00:00 PM)

60

+0.6 (+1.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-04
Earnings (Next)04-21
Inst Owners94.17%
Inst Owner ChangeN/A
Ins Owners0.16%
Ins Owner ChangeN/A
Market Cap89.03B
Revenue(TTM)20.07B
Net Income(TTM)2.90B
Analysts85.5
Price Target91.04 (51.73%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2.84%
Min EPS beat(2)1.62%
Max EPS beat(2)4.06%
EPS beat(4)4
Avg EPS beat(4)4.68%
Min EPS beat(4)1.62%
Max EPS beat(4)10.56%
EPS beat(8)8
Avg EPS beat(8)5.56%
EPS beat(12)12
Avg EPS beat(12)5.7%
EPS beat(16)15
Avg EPS beat(16)4.38%
Revenue beat(2)1
Avg Revenue beat(2)0.04%
Min Revenue beat(2)-0.88%
Max Revenue beat(2)0.96%
Revenue beat(4)3
Avg Revenue beat(4)0.87%
Min Revenue beat(4)-0.88%
Max Revenue beat(4)2.43%
Revenue beat(8)7
Avg Revenue beat(8)1.73%
Revenue beat(12)11
Avg Revenue beat(12)2.08%
Revenue beat(16)13
Avg Revenue beat(16)1.59%
PT rev (1m)-15.64%
PT rev (3m)-16.54%
EPS NQ rev (1m)-0.19%
EPS NQ rev (3m)-0.35%
EPS NY rev (1m)-0.16%
EPS NY rev (3m)-0.05%
Revenue NQ rev (1m)-0.1%
Revenue NQ rev (3m)-0.36%
Revenue NY rev (1m)-0.46%
Revenue NY rev (3m)-0.45%
Valuation
Industry RankSector Rank
PE 22.81
Fwd PE 19.89
P/S 5.14
P/FCF 28.21
P/OCF 22.76
P/B 4.26
P/tB N/A
EV/EBITDA 20.99
EPS(TTM)2.63
EY4.38%
EPS(NY)3.02
Fwd EY5.03%
FCF(TTM)2.13
FCFY3.54%
OCF(TTM)2.64
OCFY4.39%
SpS11.67
BVpS14.09
TBVpS-0.62
PEG (NY)1.56
PEG (5Y)0.88
Graham Number28.87
Profitability
Industry RankSector Rank
ROA 6.64%
ROE 11.96%
ROCE 10.46%
ROIC 8.7%
ROICexc 9.17%
ROICexgc 30.32%
OM 19.92%
PM (TTM) 14.44%
GM 69.01%
FCFM 18.22%
ROA(3y)5.27%
ROA(5y)4.17%
ROE(3y)9.54%
ROE(5y)7.64%
ROIC(3y)7.7%
ROIC(5y)7.08%
ROICexc(3y)7.95%
ROICexc(5y)7.36%
ROICexgc(3y)27.25%
ROICexgc(5y)24.65%
ROCE(3y)9.26%
ROCE(5y)8.51%
ROICexgc growth 3Y16.23%
ROICexgc growth 5Y30.87%
ROICexc growth 3Y13.89%
ROICexc growth 5Y25.4%
OM growth 3Y6.86%
OM growth 5Y16.97%
PM growth 3Y41.81%
PM growth 5YN/A
GM growth 3Y0.01%
GM growth 5Y1.13%
F-Score7
Asset Turnover0.46
Health
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF 3.13
Debt/EBITDA 2.08
Cap/Depr 64.04%
Cap/Sales 4.36%
Interest Coverage 12.54
Cash Conversion 84.48%
Profit Quality 126.23%
Current Ratio 1.62
Quick Ratio 1.08
Altman-Z 4.22
F-Score7
WACC10.25%
ROIC/WACC0.85
Cap/Depr(3y)61.91%
Cap/Depr(5y)57.64%
Cap/Sales(3y)4.69%
Cap/Sales(5y)4.67%
Profit Quality(3y)127.68%
Profit Quality(5y)132.57%
High Growth Momentum
Growth
EPS 1Y (TTM)21.51%
EPS 3Y20.34%
EPS 5Y26.01%
EPS Q2Q%14.29%
EPS Next Y14.65%
EPS Next 2Y13.93%
EPS Next 3Y13.32%
EPS Next 5Y13.13%
Revenue 1Y (TTM)19.88%
Revenue growth 3Y16.54%
Revenue growth 5Y15.16%
Sales Q2Q%15.9%
Revenue Next Year10.92%
Revenue Next 2Y10.66%
Revenue Next 3Y10.49%
Revenue Next 5Y10.46%
EBIT growth 1Y30.81%
EBIT growth 3Y24.54%
EBIT growth 5Y34.7%
EBIT Next Year24.64%
EBIT Next 3Y16.7%
EBIT Next 5Y14.81%
FCF growth 1Y38.35%
FCF growth 3Y57.4%
FCF growth 5Y29.98%
OCF growth 1Y32.03%
OCF growth 3Y43.76%
OCF growth 5Y24.63%

BOSTON SCIENTIFIC CORP / BSX.DE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of BOSTON SCIENTIFIC CORP (BSX.DE) stock?

ChartMill assigns a fundamental rating of 6 / 10 to BSX.DE.


What is the valuation status for BSX stock?

ChartMill assigns a valuation rating of 4 / 10 to BOSTON SCIENTIFIC CORP (BSX.DE). This can be considered as Fairly Valued.


How profitable is BOSTON SCIENTIFIC CORP (BSX.DE) stock?

BOSTON SCIENTIFIC CORP (BSX.DE) has a profitability rating of 8 / 10.


What is the valuation of BOSTON SCIENTIFIC CORP based on its PE and PB ratios?

The Price/Earnings (PE) ratio for BOSTON SCIENTIFIC CORP (BSX.DE) is 22.81 and the Price/Book (PB) ratio is 4.26.


Can you provide the expected EPS growth for BSX stock?

The Earnings per Share (EPS) of BOSTON SCIENTIFIC CORP (BSX.DE) is expected to grow by 14.65% in the next year.